Personalized Immunotherapy for Stage III Lung Cancer
Treatments studied
This study tests a personalized immunotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. The treatment is given after standard chemoradiation, and the study aims to see if it improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have stage III non-small cell lung cancer that cannot be surgically removed.
- You must be fit enough to receive chemotherapy and radiation therapy, with a good performance status (ECOG 0-1).
- Your tumor must not have certain genetic mutations (EGFR, ALK, HER2).
- You must not have had radiation to the chest or chemotherapy for cancer within the last 3 years.
- You must not have an active autoimmune disease or be on high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests whether tailoring the next (add-on) treatments can improve outcomes after standard chemoradiation and immunotherapy for stage III, unresectable (not operable) non-small cell lung cancer. It specifically looks at giving durvalumab plus an additional drug (tremelimumab) and possibly other consolidation chemotherapy based on a personalized plan.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy (durvalumab) for people with stage III non-small cell lung cancer that cannot be removed with surgery. The goal is to see if giving a smaller, more focused radiation dose can be just as effective with fewer side effects.
This trial tests a combination of immunotherapy, chemotherapy, and either surgery or radiation for people with stage IIIA or IIIB non-small cell lung cancer. The goal is to see if adding the drug durvalumab after standard treatment helps control the cancer better.
This trial tests a personalized combination of radiation and immunotherapy for people with locally advanced non-small cell lung cancer that has a high level of a protein called PD-L1. It aims to improve treatment by tailoring the therapy to each patient's tumor.
This trial tests if giving the immunotherapy drug durvalumab after chemoradiation and surgery helps people with stage 3 non-small cell lung cancer. You will receive standard chemoradiation, then have surgery, and then get durvalumab to see if it lowers the chance of the cancer coming back.
This study tests a new combination of radiation therapy, an immunotherapy drug called tislelizumab, and chemotherapy for people with bulky stage III non-small cell lung cancer. The goal is to see if this approach can shrink tumors more effectively and improve outcomes.
Hear when a new Non-small Cell Lung Cancer Stage III Unresectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.